Marshall Wace, LLP Cue Biopharma, Inc. Transaction History

Marshall Wace, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$2.23 - $3.37 $61,918 - $93,571	-27,766 Reduced 51.45%	26,205 $58,000
Q2 2022 Aug 15, 2022	BUY	$2.49 - $5.92 $134,387 - $319,508	53,971 New	53,971 $134,000
Q4 2021 Feb 14, 2022	SELL	$10.86 - $17.85 $286,052 - $470,169	-26,340 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$10.06 - $15.3 $53,478 - $81,334	-5,316 Reduced 16.79%	26,340 $384,000
Q2 2021 Aug 13, 2021	BUY	$10.9 - $14.53 $345,050 - $459,961	31,656 New	31,656 $369,000
Q1 2021 May 17, 2021	SELL	$11.2 - $16.09 $423,875 - $608,942	-37,846 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$11.12 - $16.4 $420,847 - $620,674	37,846 New	37,846 $473,000
Q1 2020 May 15, 2020	SELL	$9.85 - $22.27 $985 - $2,227	-100 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$7.06 - $17.47 $706 - $1,747	100 New	100 $2,000

14.1M

14.4K

2.6K

Ticker CUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,381,700
Market Cap $38.2M
Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.